BRPI1014277A2 - método para melhorar o perfil de dissolução de um material biologicamente ativo - Google Patents

método para melhorar o perfil de dissolução de um material biologicamente ativo

Info

Publication number
BRPI1014277A2
BRPI1014277A2 BRPI1014277A BRPI1014277A BRPI1014277A2 BR PI1014277 A2 BRPI1014277 A2 BR PI1014277A2 BR PI1014277 A BRPI1014277 A BR PI1014277A BR PI1014277 A BRPI1014277 A BR PI1014277A BR PI1014277 A2 BRPI1014277 A2 BR PI1014277A2
Authority
BR
Brazil
Prior art keywords
improving
active material
biologically active
dissolution profile
dissolution
Prior art date
Application number
BRPI1014277A
Other languages
English (en)
Inventor
Aaron Dodd
Adrian Russell
Felix Meiser
Matt Callahan
Marck Norret
William H Bosch
Original Assignee
Iceutica Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2009901741A external-priority patent/AU2009901741A0/en
Application filed by Iceutica Pty Ltd filed Critical Iceutica Pty Ltd
Publication of BRPI1014277A2 publication Critical patent/BRPI1014277A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/12—Powders or granules
    • A01N25/14—Powders or granules wettable
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
BRPI1014277A 2009-04-24 2010-04-23 método para melhorar o perfil de dissolução de um material biologicamente ativo BRPI1014277A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17230109P 2009-04-24 2009-04-24
AU2009901741A AU2009901741A0 (en) 2009-04-24 Method for Improving the Dissolution Profile of a Biologically Active Material
PCT/AU2010/000465 WO2010121321A1 (en) 2009-04-24 2010-04-23 Method for improving the dissolution profile of a biologically active material

Publications (1)

Publication Number Publication Date
BRPI1014277A2 true BRPI1014277A2 (pt) 2016-10-18

Family

ID=43010604

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1014277A BRPI1014277A2 (pt) 2009-04-24 2010-04-23 método para melhorar o perfil de dissolução de um material biologicamente ativo

Country Status (21)

Country Link
US (5) US20120165323A1 (pt)
EP (1) EP2421516A4 (pt)
JP (3) JP5898613B2 (pt)
KR (3) KR20120047207A (pt)
CN (3) CN104825396A (pt)
AP (2) AP3629A (pt)
AU (2) AU2010239160B2 (pt)
BR (1) BRPI1014277A2 (pt)
CA (1) CA2759104C (pt)
CO (1) CO6470804A2 (pt)
EA (1) EA201171280A1 (pt)
IL (1) IL215871B (pt)
MA (1) MA33293B1 (pt)
MX (1) MX360545B (pt)
MY (1) MY163538A (pt)
NZ (1) NZ595972A (pt)
PH (1) PH12015501781A1 (pt)
SG (1) SG175308A1 (pt)
UA (1) UA110772C2 (pt)
WO (1) WO2010121321A1 (pt)
ZA (1) ZA201108647B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5508003B2 (ja) 2006-06-30 2014-05-28 アイスイティカ ピーティーワイ リミテッド ナノ粒子状の形態における生物学的に活性な化合物の調製のための方法
US20120148634A1 (en) * 2009-04-24 2012-06-14 Aaron Dodd Novel formulation of naproxen
AP3629A (en) * 2009-04-24 2016-03-08 Iceutica Pty Ltd Method for improving the dissolution profile of a biologically active material
CN102438593A (zh) * 2009-04-24 2012-05-02 伊休蒂卡有限公司 高体积分数的包封纳米颗粒的制备
AU2010239081C1 (en) 2009-04-24 2014-11-06 Iceutica Pty Ltd A novel formulation of indomethacin
WO2010121322A1 (en) * 2009-04-24 2010-10-28 Iceutica Pty Ltd Production of encapsulated nanoparticles at commercial scale
AU2010239082B2 (en) * 2009-04-24 2014-10-16 Iceutica Pty Ltd A novel formulation of metaxalone
WO2014152207A1 (en) * 2013-03-15 2014-09-25 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
CN104644556B (zh) * 2013-11-22 2018-05-22 沈阳药科大学 盐酸依福地平固体粉末及其制备方法
AU2015200340B2 (en) * 2014-02-05 2019-01-24 Upl Limited Combinations
US11175268B2 (en) 2014-06-09 2021-11-16 Biometry Inc. Mini point of care gas chromatographic test strip and method to measure analytes
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
AU2015274801B2 (en) 2014-06-09 2020-10-15 Biometry Inc. Low cost test strip and method to measure analyte
AU2016278846B2 (en) * 2015-06-19 2021-08-05 Biotie Therapies, Inc. Controlled-release tozadenant formulations
BR112018006504B1 (pt) * 2015-10-23 2022-07-12 Basf Se Formulação solúvel em água, e, uso das formulações solúveis em água
CN105385739B (zh) * 2015-12-09 2017-09-29 梁尚文 －种从金边蚂蟥中制取蛋白肽的方法
JP7086927B2 (ja) 2016-07-19 2022-06-20 バイオメトリー・インコーポレイテッド バッチ校正可能なテストストリップを用いる検体測定方法と検体測定システム
CN107853670A (zh) * 2017-10-30 2018-03-30 潍坊友容实业有限公司 一种盐地碱蓬生物盐提取方法
CN108379238B (zh) * 2018-01-17 2020-07-14 南昌大学 一种储存物理稳定性好的环孢素固体脂质纳米粒及其制备方法
US20210106591A1 (en) 2018-05-11 2021-04-15 Nanjing Delova Biotech Co. Ltd. Meloxicam composition, preparation and preparation method and use thereof
WO2020046559A1 (en) * 2018-08-31 2020-03-05 Kemin Industries, Inc. Technology for water dispersible phospholipids and lysophospholipids
WO2020073033A1 (en) * 2018-10-05 2020-04-09 Ampersand Biopharmaceuticals, Inc. Formulations and methods for transdermal administration of ketones
US11197830B2 (en) 2019-02-27 2021-12-14 Aft Pharmaceuticals Limited Pharmaceutical composition containing acetaminophen and ibuprofen
CN113133970A (zh) * 2020-01-17 2021-07-20 美国琛蓝营养制品股份有限公司 一种姜黄素复合物及其制备方法和检测方法
TR202017034A2 (tr) * 2020-10-26 2021-09-21 Hacettepe Ueniversitesi Rektoerluek Kuru öğütme yöntemi̇ i̇le hazirlanan ve çözünme hizi arttirilmiş selekoksi̇b i̇çeren farmasöti̇k kompozi̇syonlar
CN114306253B (zh) * 2021-11-16 2023-08-22 扬子江药业集团广州海瑞药业有限公司 格列美脲片剂及其制备方法
CN113996161B (zh) * 2021-12-30 2022-04-19 河北鑫鹏新材料科技有限公司 一种硫转移剂及其制备方法和应用
CN114732009B (zh) * 2022-06-13 2022-08-23 山东百农思达生物科技有限公司 一种含有吡唑醚菌酯和烯酰吗啉的水分散粒剂的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
AU660852B2 (en) * 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
JP4117811B2 (ja) * 1997-04-22 2008-07-16 日本化薬株式会社 フルタミド製剤及びその製法
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
AU8847101A (en) * 2000-08-31 2002-03-13 Rtp Pharma Inc Milled particles
JP2004099442A (ja) * 2002-09-04 2004-04-02 Nisshin Pharma Inc 難溶性薬物含有製剤およびその製造方法
BRPI0518101A (pt) * 2004-12-31 2008-10-28 Iceutica Pty Ltd métodos de produção e sìntese de composições nanoparticuladas, composições obtidas e seu uso
ES2334164T3 (es) * 2005-12-15 2010-03-05 Acusphere, Inc. Procedimiento de preparacion de formulaciones farmaceuticas a base de particulas para administracion parenteral.
CA2631493A1 (en) * 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
US8808751B2 (en) * 2006-06-30 2014-08-19 Iceutica Pty Ltd. Methods for the preparation of biologically active compounds in nanoparticulate form
JP5508003B2 (ja) * 2006-06-30 2014-05-28 アイスイティカ ピーティーワイ リミテッド ナノ粒子状の形態における生物学的に活性な化合物の調製のための方法
AU2010239081C1 (en) * 2009-04-24 2014-11-06 Iceutica Pty Ltd A novel formulation of indomethacin
AP3629A (en) * 2009-04-24 2016-03-08 Iceutica Pty Ltd Method for improving the dissolution profile of a biologically active material
BRPI1014272A2 (pt) * 2009-04-24 2016-10-18 Iceutica Pty Ltd nova formulação de diclofenac

Also Published As

Publication number Publication date
PH12015501781A1 (en) 2016-10-03
US20210401753A1 (en) 2021-12-30
KR101873500B1 (ko) 2018-08-02
AU2010239160A1 (en) 2011-11-10
AP2011005994A0 (en) 2011-12-31
MX2011011217A (es) 2012-02-08
KR101679522B1 (ko) 2016-11-24
EP2421516A1 (en) 2012-02-29
MA33293B1 (fr) 2012-05-02
MY163538A (en) 2017-09-15
SG175308A1 (en) 2011-11-28
CN102438600A (zh) 2012-05-02
IL215871A0 (en) 2012-01-31
WO2010121321A1 (en) 2010-10-28
IL215871B (en) 2019-07-31
US20180169018A1 (en) 2018-06-21
AU2010239160B2 (en) 2014-10-02
JP2017222643A (ja) 2017-12-21
JP6619386B2 (ja) 2019-12-11
CO6470804A2 (es) 2012-06-29
AP3629A (en) 2016-03-08
JP5898613B2 (ja) 2016-04-06
EA201171280A1 (ru) 2012-09-28
KR20160098535A (ko) 2016-08-18
EP2421516A4 (en) 2012-11-07
US20200375903A1 (en) 2020-12-03
AU2015243003A1 (en) 2017-05-04
ZA201108647B (en) 2013-01-30
CA2759104C (en) 2019-01-29
CN104825396A (zh) 2015-08-12
AP2015008965A0 (en) 2016-01-31
JP2015199736A (ja) 2015-11-12
KR20120047207A (ko) 2012-05-11
CN103830243A (zh) 2014-06-04
US20130277468A1 (en) 2013-10-24
MX360545B (es) 2018-10-26
NZ595972A (en) 2014-01-31
US20120165323A1 (en) 2012-06-28
JP2012524717A (ja) 2012-10-18
CA2759104A1 (en) 2010-10-28
KR20150013948A (ko) 2015-02-05
UA110772C2 (uk) 2016-02-25

Similar Documents

Publication Publication Date Title
BRPI1014277A2 (pt) método para melhorar o perfil de dissolução de um material biologicamente ativo
BR112013012801A2 (pt) método para a produção de um calçado e calçado
BRPI1015095A2 (pt) composição, processos para preparar uma composição e um material de poli-isocianurato , e, material de poli-isocianurato
BRPI1007709A2 (pt) "artigo e método para a preparação de um artigo"
BRPI0923748A2 (pt) Método para a preparação de dióis
BR112012003365A2 (pt) método e dispositivo para a fabricação de objetos de titânio.
BRPI0819946A2 (pt) Composição de matéria e método para preparar uma composição tensoativa
BRPI1013561A8 (pt) processo para a preparação de alogliptina
BRPI1009189A2 (pt) método para melhorar o rendimento de um polipetídeo
BR112013011856A2 (pt) sistema de implante dental e processo para a fabricação de um sistema de implante dental
BRPI1013219A2 (pt) método para o alvejamento-branqueamento enzimático têxtil
BRPI0915208A2 (pt) método e aparelho para a fabricação de material lignocelulósico torrificado
BRPI1007160A2 (pt) Método para esterilizar um material
BR112012002102A2 (pt) composição farmaceutica e metodo para preparar uma composição farmaceutica
BRPI0922490A2 (pt) Método para produção de beta-santaleno
ZA201106789B (en) A method of reducing the arte of degradation of a biological material
DK2445543T3 (da) Knogleerstatnings-materiale
FR2948037B1 (fr) Materiau photocatalytique
BR112012000420A2 (pt) método de dispensação de droga
BR112012001731A2 (pt) Processo para a preparação de 1-benzil-3-hidroximetil-1h-indazol
BRPI0924621A2 (pt) método para calibração de superfícies de material de pedra
BRPI0914792A2 (pt) processo para a preparação de polióis
BRPI1010841A2 (pt) método para a fabricação de fluoroalquilnitrilas
BRPI0922087A2 (pt) Processos para fabricar um composto e para preparar um composto
BR112013014581A2 (pt) método para a fabricação de um diorgano-di-halossilano

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]